Table 1.
Subject characteristics and baseline hemodynamics
|
Protocol 1: Drug Order |
|||
|---|---|---|---|
| Variable | l-NMMA + Ket | Ket + l-NMMA | Protocol 2: Combined Inhibition Before AA |
| Male:female | 3:3 | 4:4 | 2:3 |
| Age, yr | 66 ± 3 | 62 ± 2 | 64 ± 2 |
| Body mass index, kg/m2 | 24.3 ± 0.5 | 26.0 ± 1.0 | 23.3 ± 0.7 |
| Body fat, % | 24.5 ± 2.0 | 31.0 ± 2.3 | 28.9 ± 4.2 |
| Forearm FFM, g | 740 ± 87 | 746 ± 105 | 737 ± 105 |
| Forearm volume, ml | 933 ± 84 | 951 ± 92 | 782 ± 92 |
| MVC, kg | 38 ± 4 | 36 ± 4 | 32 ± 4 |
| 10% MVC, kg | 3.8 ± 0.4 | 3.6 ± 0.4 | 3.2 ± 0.4 |
| Total cholesterol, mmol/l | 4.1 ± 0.1 | 4.6 ± 0.2 | 4.7 ± 0.3 |
| LDL cholesterol, mmol/ | 2.4 ± 0.2 | 2.8 ± 0.2 | 3.1 ± 0.3 |
| HDL cholesterol, mmol/l | 1.2 ± 0.2 | 1.2 ± 0.2 | 1.2 ± 0.2 |
| Triglycerides, mmol/l | 1.0 ± 0.2 | 1.2 ± 0.3 | 0.9 ± 0.1 |
| Mean arterial pressure, mmHg | 93 ± 5 | 93 ± 4 | 91 ± 4 |
| HR, beats/min | 60 ± 3 | 63 ± 3 | 54 ± 3 |
| Forearm blood flow, ml/min | 33 ± 6 | 43 ± 6 | 36 ± 8 |
| Forearm VC, ml•min−1•100 mmHg−1 | 36 ± 7 | 36 ± 7 | 40 ± 8 |
Data are presented as means ± SE. l-NMMA, NG-monomethyl-l-arginine; Ket, ketorolac; AA ascorbic acid; FFM, fat-free mass; MVC, maximal voluntary contraction; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HR, heart rate; VC, vascular conductance.